Optimizing Treatment Strategies for Adult Attention-Deficit Hyperactivity Disorder (ADHD) (R01 Clinical Trial Required)

The objective of this NOFO is to provide evidence for the optimal treatment of ADHD in adults, given its relatively recent acceptance as a formal diagnostic category. While stimulant drugs offer the advantages of rapid onset of action and history of efficacy, the risk of adverse effects, dependence, misuse, and diversion, along with recent medication shortages, underscore the importance of studying evidence-based complementary and alternative approaches when indicated. Clinical trials testing non-stimulant medications, psychosocial interventions, and device-based approaches, sequentially or in combination, to augment or replace stimulants in situations where stimulant monotherapy is insufficiently effective, difficult to tolerate, or undesirable, in the acute and post-acute treatment of ADHD in adults, or in preventing the transition of ADHD symptoms from adolescence to adulthood, will be supported by this NOFO.

The objective of this NOFO is to provide evidence for the optimal treatment of ADHD in adults, given its relatively recent acceptance as a formal diagnostic category. While stimulant drugs offer the advantages of rapid onset of action and history of efficacy, the risk of adverse effects, dependence, misuse, and diversion, along with recent medication shortages, underscore the importance of studying evidence-based complementary and alternative approaches when indicated. Clinical trials testing non-stimulant medications, psychosocial interventions, and device-based approaches, sequentially or in combination, to augment or replace stimulants in situations where stimulant monotherapy is insufficiently effective, difficult to tolerate, or undesirable, in the acute and post-acute treatment of ADHD in adults, or in preventing the transition of ADHD symptoms from adolescence to adulthood, will be supported by this NOFO.

Other Eligible Applicants include the following:
Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply.

Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.

Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.